Craft

NeoGenomics

Stock Price

$13.5

2024-10-29

Market Capitalization

$1.7 B

2024-10-29

Revenue

$727.3 M

FY, 2025

NeoGenomics Summary

Company Summary

Overview
NeoGenomics Laboratories is a provider of oncology diagnostic testing and consultative services. It offers cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry and digital imaging, molecular testing, and morphologic analysis services. The company also specializes in Molecular and NGS testing, Clinical trials and research, Validation laboratory operations, and Oncology data management. NeoGenomics Laboratories serves hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers.
Type
Public
Status
Active
Founded
2002
HQ
Fort Myers, FL, US | view all locations
Website
https://neogenomics.com
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Chris Smith

    Chris Smith, Chief Executive Officer

  • Maher Albitar

    Maher Albitar, Chief Medical Officer and Director of Research and Development

    • Douglas Brown

      Douglas Brown, Chief Strategy and Corporate Development Officer

      • Halley Gilbert

        Halley Gilbert, Chief Legal Officer

        Operating MetricsView all

        Facility Space, sq. ft.

        533.4K
        37.6%

        FY, 2021

        Testing Services

        6

        Q3, 2022

        Facility Space Owned (Corporate), sq.ft.

        43.6K

        Q3, 2022

        LocationsView all

        11 locations detected

        • Fort Myers, FL HQ

          United States

          9490 NeoGenomics Way

        • Aliso Viejo, CA

          United States

          31 Columbia

        • Atlanta, GA

          United States

          2800 Century Pkwy NE, Suite 250

        • Carlsbad, CA

          United States

          2173 Salk Ave #300

        • Fort Myers, FL

          United States

          12701 Commonwealth Dr., Suite 9

        • Houston, TX

          United States

          7256 South Sam Houston Parkway West, #300

        and 5 others

        NeoGenomics Financials

        Summary Financials

        Revenue (Q1, 2026)
        $186.7M
        Gross profit (Q1, 2026)
        $80.9M
        Net income (Q1, 2026)
        ($17.1M)
        Cash (Q1, 2026)
        $146.1M
        EBIT (Q1, 2026)
        ($18.2M)
        Enterprise value
        $2.0B

        Footer menu